Autologous or allogeneic bone marrow transplantation for acute myeloblastic leukemia in second complete remission. Importance of duration of first complete remission in final outcome

Bone Marrow Transplantation

Volumn 17, Issue 6, 1996, Pages 979-984

  Tomas J F ^a   Gomez Garcia De Soria V ^a   Lopez Lorenzo J L ^a   Arranz, R ^a   Figuera, A ^a   Camara R ^a   Alegre, A ^a   Fernandez Ranada J M ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Allo BMT; AML; Auto BMT; Second remission

Indexed keywords

BUSULFAN; CYCLOSPORIN; CYCLOSPORIN A; METHOTREXATE;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CHILD; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; RECURRENCE; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030057329     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Mayer R, Davis RB, Schiffer CA et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. New Engl J Med 1994; 331: 896-903.
2. Bortin M, Horowitz MM, Rowlings PA et al. 1993 Progress report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1993; 12: 97-104.
3. Stuart RK. Autologous bone marrow transplantation for leukemia. Semin Oncol 1993; 20 (Suppl. 6): 40-54.
4. Hurd D. Postremission therapy for the younger adult patient with acute myelogenous leukemia: defining a role for transplantation. J Clin Oncol 1993; 11: 1636-1638.
5. Davis CL, Rohatiner AZS, Lim J et al. The management of recurrent acute myelogenous leukemia at a single center over a fifteen-year period. Br J Haematol 1993; 83: 404-411.
6. Clift R. The treatment of acute nonlymphoblastic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant 1987; 2: 243-258.
7. Gorin N, Labopin M, Meloni G et al. Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: further evidence of the role of marrow purging by mafosfamide. Leukemia 1991; 5: 896-904.
8. Chopra R, Goldstone AH, McMillan AK. Successful treatment of acute myeloid leukemia beyond first remission with autologous bone marrow transplantation using busulphan/cyclophosphamide and unpurged marrow: The British Autograft Group experience. J Clin Oncol 1991; 9: 1840-1847.
9. Linker C, Ries CA, Damon LE et al. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood 1993; 81: 311-318.
10. Meloni G, De Fabritiis P, Petti MC et al. BAVC regimen and autologous bone marrow transplantation in patients with acute myelogenous leukemia in second remission. Blood 1990; 75: 2282-2285.
11. Ball E, Mills LE, Cornwell GG III et al. Autologous bone marrow transplantation for acute myeloid leukemia using monoclonal antibody-purged bone marrow. Blood 1990; 75: 1199-1206.
12. Selvaggi K, Wilson JW, Mills LE et al. Improved outcome for high-risk acute myeloid leukemia patients using autologous bone marrow transplantation and monoclonal antibody-purged bone marrow. Blood 1994; 83: 1698-1705.
13. Yeager A, Kaizer H, Santos GW et al. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia using ex vivo marrow treatment with 4-HC to purge tumor cells. New Engl J Med 1986; 315: 141-147.
14. Higuchi C, Thompson JA, Petersen FB et al. Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood 1991; 77: 2561-2568.
15. Klingemann H. Immunotherapy after bone marrow transplantation. Bone Marrow Transplant 1991; 8: 73-81.
16. Zittoun R, Liso V, Mandelli F et al. Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission: an EORTC/Gimema phase III trial (AML 8B). Leukemia 1992; 6 (Suppl. 2): 76-77.
17. DelaSerna J, Tomás JF, Solano C et al. Idarubicin plus intermediate dose ARA-C for treatment of refractory and relapsing adult acute myelogenous leukemia. Blood 1994; 84 (Suppl. 1): 304a (Abstr.).
18. Tomás JF, Hernández L, Peñarrubia MJ et al. Infecciones bacterianas precoces en 103 pacientes tratados con trasplante de médula ósea. Sangre 1994; 39: 191-196.
19. Cámara R, Tomás JF, Figuera A et al. High dose busulfan and seizures. Bone Marrow Transplant 1991; 7: 362-364.
20. Cámara R, Peñarrubia MJ, Cardeñoso L et al. CMV prophylaxis in allogeneic BMT: results of a prospective study. Bone Marrow Transplant 1995; 15 (Suppl. 2): 532 (Abstr).
21. Storb R, Deeg HJ, Withehead J et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. New Engl J Med 1986; 314: 729-735.
22. Deeg HJ, Storb R. Acute graft-versus-host disease: clinical manifestations, prophylaxis, and treatment. J Natl Clin Invest 1986; 76: 1325-1328.
23. Hervé P, Wijdenes J, Bergerat JP et al. Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 monoclonal antibody (B-B10). Blood 1990; 75: 1017-1023.
24. Sullivan KM, Shulman HM, Storb R et al. Chronic graft-versus-host disease in fifty-two patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267-276.
25. McDonald GB, Sharma P, Matthews DE et al. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116-122.
26. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
27. Cox DR. Regression models and life-table. J R Stat Soc (B) 1972; 34: 187-220.
28. Keating A, Rowling PA, Horowitz MM et al for the IBMTR and the NAABMTR. Comparison of HLA-identical sibling and autologous bone marrow transplants for acute myelogenous leukemia (AML). Blood 1994; 84 (Suppl. 1): 201a (Abstr. 789).
29. Locasciulli A, Bacigalupo A, Van Lint MT et al. Hepatitis C virus infection in patients undergoing allogeneic bone marrow transplantation. Transplantation 1991; 52: 315-320.
30. Maruta A, Kanamori H, Fukawa H et al. Liver function tests of recipients with hepatitis C virus infection after marrow transplantation. Bone Marrow Transplant 1994; 13: 417-422.
31. Sanz M, de la Rubia J, Sanz GF et al. Busulfan plus cyclophosphamide followed by autologous blood stem-cell transplantation for patients with acute myeloblastic leukemia in first complete remission: a report from a single institution. J Clin Oncol 1993; 11: 1661-1667.
32. Estey EH. Use of colony-stimulating factors in the treatment of acute myeloid leukemia. Blood 1994; 83: 2015-2019.
33. Kantarjian HM, Keating MJ, Walters RS et al. The characteristics and outcome of patients with late relapsed acute myelogenous leukemia. J Clin Oncol 1988; 6: 232-238.
34. Berman E, Little C, Gee T et al. Reasons that patients with acute myelogenous leukemia do not undergo allogeneic marrow transplantation. New Engl J Med 1992; 326: 156-160.
35. Gray R, Wheatly K. How to avoid bias when comparing bone marrow transplantation with chemotherapy. Bone Marrow Transplant 1992; 7 (Suppl. 3): 9-12.